Erytech up on Graspa Phase III data

Erytech Pharma S.A. (Euronext:ERYP) climbed EUR 3.33 (13%) to EUR 29.50 on Wednesday after it said Graspa met the co-primary endpoints in the GRASPIVOTALL Phase III trial to treat children and adults with relapsed or refractory acute lymphoblastic leukemia (ALL).

The 80 patient study compared the L-asparaginase encapsulated in red blood cells to non-encapsulated L-asparaginase, in combination with standard chemotherapy. The co-primary endpoints were a statistically significant reduction in allergic reactions and a statistically significant increase in the duration of circulating asparaginase activity. ...